Yongping Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yongping Zhang has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Boran Li
Center for Metabolism Research, The Fourth Affiliated Hospital of Zhejiang University School of Medicine and International School of Medicine, International Institutes of Medicine, Zhejiang University 1 Department of Respiratory and Critical Care Medicine Yiwu
1 shared publication - Caihua Chang
Department of Infectious Diseases People's Hospital of Xinjiang Uygur Autonomous Region Urumqi China
1 shared publication - Chang-Qing Xia
Department of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE 68198, USA
1 shared publication - Chen Cheng
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
1 shared publication - Dongmei Zhang
Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine
1 shared publication - Hai-Yin Jiang
Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
1 shared publication
Latest Publications
- Open Access
- 25 August 2021
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 35 (10) , e23974
MRD abnormal expression predict poor outcomes for refractory or relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
We retrospectively analyzed data from 197 patients with refractory or relapsed acute myeloid leukemia (r/rAML) who underwent allo‐HCT between January 2013 and February 2020 in our center (patients with promyelocytic leukemia were excluded). Of all patients, 86 achieved a complete morphological remission (CR) before transplant, while 111 failed to do so (NR). In the CR group, 32 patients displayed minimal residual disease (MRD‐positive). According to their immunophenotype pre‐HCT, we divided the MRD‐positive group and NR group into three subgroups: MRD 0+ group (without any antigen abnormal expression of CD7+, CD56+, CD38−, or HLA‐DR−) 28 patients, MRD 1+ group (with one abnormal antigen expression of CD7+, CD56+, CD38−, or HLA‐DR−) 63 patients, MRD 2+ group (with two or more abnormal antigens expression of CD7+, CD56+, CD38‐, or HLA‐DR‐) 52 patients. 3‐year estimates of disease‐free survival (DFS) for MRD 0+, MRD 1+ and MRD 2+ patients were 59.5 ± 9.5%, 29.9 ± 6.1%, and 9.4 ± 5.1%, and 3‐year estimates of overall survival (OS) were 59.5 ± 9.5%, 34.5 ± 6.3%, and 14.5 ± 10.8%, respectively. Multivariate analysis adjusted for genetic risk, blast cell level, secondary disease, age, sex, and donor relationship pre‐HCT, the hazard ratios of abnormal expression of CD7+, CD56+, HLA‐DR−, and CD38‐ were 6.69 (range 2.08–21.52; p = 0.001) for DFS, 2.24 (range 1.21–4.14; p = 0.010) for OS, and 7.18 (range 2.23–23.10; p = 0.001) for relapse compared with CD7−, CD56−, HLA‐DR+, and CD38+ patients. Our finding suggested that abnormal expression of CD7+, CD56+, HLA‐DR−, and CD38− is associated with poor outcomes, and the more number of abnormal antigens expression predict worse outcomes.
- 25 August 2021
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 35 (10) , e23974
Open AccessMRD abnormal expression predict poor outcomes for refractory or relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
We retrospectively analyzed data from 197 patients with refractory or relapsed acute myeloid leukemia (r/rAML) who underwent allo‐HCT between January 2013 and February 2020 in our center (patients with promyelocytic leukemia were excluded). Of all patients, 86 achieved a complete morphological remission (CR) before transplant, while 111 failed to do so (NR). In the CR group, 32 patients displayed minimal residual disease (MRD‐positive). According to their immunophenotype pre‐HCT, we divided the MRD‐positive group and NR group into three subgroups: MRD 0+ group (without any antigen abnormal expression of CD7+, CD56+, CD38−, or HLA‐DR−) 28 patients, MRD 1+ group (with one abnormal antigen expression of CD7+, CD56+, CD38−, or HLA‐DR−) 63 patients, MRD 2+ group (with two or more abnormal antigens expression of CD7+, CD56+, CD38‐, or HLA‐DR‐) 52 patients. 3‐year estimates of disease‐free survival (DFS) for MRD 0+, MRD 1+ and MRD 2+ patients were 59.5 ± 9.5%, 29.9 ± 6.1%, and 9.4 ± 5.1%, and 3‐year estimates of overall survival (OS) were 59.5 ± 9.5%, 34.5 ± 6.3%, and 14.5 ± 10.8%, respectively. Multivariate analysis adjusted for genetic risk, blast cell level, secondary disease, age, sex, and donor relationship pre‐HCT, the hazard ratios of abnormal expression of CD7+, CD56+, HLA‐DR−, and CD38‐ were 6.69 (range 2.08–21.52; p = 0.001) for DFS, 2.24 (range 1.21–4.14; p = 0.010) for OS, and 7.18 (range 2.23–23.10; p = 0.001) for relapse compared with CD7−, CD56−, HLA‐DR+, and CD38+ patients. Our finding suggested that abnormal expression of CD7+, CD56+, HLA‐DR−, and CD38− is associated with poor outcomes, and the more number of abnormal antigens expression predict worse outcomes.
- 10 August 2021
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (3) , 911-918
Neonatal outcomes after neuraminidase inhibitor use during pregnancy: A meta‐analysis of cohort studies
Aim: Influenza infection poses a severe threat to pregnant mothers, and antiviral treatment is recommended. However, the safety of neuraminidase‐inhibitor antiviral medications during pregnancy has not been well described.Methods: A systematic review and meta‐analysis were performed to evaluate the adverse neonatal outcomes associated with exposure to neuraminidase inhibitors during pregnancy. The PubMed, Embase and Cochrane Library databases were searched to identify potential studies for inclusion.Results: Nine cohort studies that estimated adverse neonatal outcomes associated with exposure to neuraminidase‐inhibitor medication during pregnancy were included. Exposure to a neuraminidase inhibitor during pregnancy was not associated with an increased risk of congenital malformation (odds ratio [OR] 0.9, 95% confidence interval [CI] 0.72‐1.12, P = .341), low Apgar score (OR 0.96, 95% CI 0.77‐1.2, P = .733) or preterm birth (OR 0.99, 95% CI 0.89‐1.09, P = .771) compared with no exposure. However, exposure to a neuraminidase inhibitor was associated with a reduced risk of low birth weight (OR 0.79, 95% CI 0.68‐0.92, P = .002) and giving birth to a small‐for‐gestational‐age infant (OR 0.78, 95% CI 0.69‐0.88, P < .001). Further analyses limited to oseltamivir exposure were consistent with the overall results.Conclusion: Exposure to neuraminidase‐inhibitor medication during pregnancy does not appear to be associated with adverse neonatal outcomes. We recommend further studies to investigate this association, which will help clinicians determine whether to prescribe a neuraminidase inhibitor during pregnancy.
- 10 August 2021
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 88 (3) , 911-918
Neonatal outcomes after neuraminidase inhibitor use during pregnancy: A meta‐analysis of cohort studies
Aim: Influenza infection poses a severe threat to pregnant mothers, and antiviral treatment is recommended. However, the safety of neuraminidase‐inhibitor antiviral medications during pregnancy has not been well described.Methods: A systematic review and meta‐analysis were performed to evaluate the adverse neonatal outcomes associated with exposure to neuraminidase inhibitors during pregnancy. The PubMed, Embase and Cochrane Library databases were searched to identify potential studies for inclusion.Results: Nine cohort studies that estimated adverse neonatal outcomes associated with exposure to neuraminidase‐inhibitor medication during pregnancy were included. Exposure to a neuraminidase inhibitor during pregnancy was not associated with an increased risk of congenital malformation (odds ratio [OR] 0.9, 95% confidence interval [CI] 0.72‐1.12, P = .341), low Apgar score (OR 0.96, 95% CI 0.77‐1.2, P = .733) or preterm birth (OR 0.99, 95% CI 0.89‐1.09, P = .771) compared with no exposure. However, exposure to a neuraminidase inhibitor was associated with a reduced risk of low birth weight (OR 0.79, 95% CI 0.68‐0.92, P = .002) and giving birth to a small‐for‐gestational‐age infant (OR 0.78, 95% CI 0.69‐0.88, P < .001). Further analyses limited to oseltamivir exposure were consistent with the overall results.Conclusion: Exposure to neuraminidase‐inhibitor medication during pregnancy does not appear to be associated with adverse neonatal outcomes. We recommend further studies to investigate this association, which will help clinicians determine whether to prescribe a neuraminidase inhibitor during pregnancy.
- 17 June 2017
- Published by Springer Nature in Frontiers of Medicine
- Vol. 11 (4) , 554-562
CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells
T cells engineered with chimeric antigen receptor (CAR) have been successfully applied to treat advanced refractory B cell malignancy. However, many challenges remain in extending its application toward the treatment of solid tumors. The immunosuppressive nature of tumor microenvironment is considered one of the key factors limiting CAR-T efficacy. One negative regulator of Tcell activity is lymphocyte activation gene-3 (LAG-3). We successfully generated LAG-3 knockout Tand CAR-T cells with high efficiency using CRISPR-Cas9 mediated gene editing and found that the viability and immune phenotype were not dramatically changed during in vitro culture. LAG-3 knockout CAR-T cells displayed robust antigen-specific antitumor activity in cell culture and in murine xenograft model, which is comparable to standard CAR-T cells. Our study demonstrates an efficient approach to silence immune checkpoint in CAR-T cells via gene editing.
- 17 June 2017
- Published by Springer Nature in Frontiers of Medicine
- Vol. 11 (4) , 554-562
CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells
T cells engineered with chimeric antigen receptor (CAR) have been successfully applied to treat advanced refractory B cell malignancy. However, many challenges remain in extending its application toward the treatment of solid tumors. The immunosuppressive nature of tumor microenvironment is considered one of the key factors limiting CAR-T efficacy. One negative regulator of Tcell activity is lymphocyte activation gene-3 (LAG-3). We successfully generated LAG-3 knockout Tand CAR-T cells with high efficiency using CRISPR-Cas9 mediated gene editing and found that the viability and immune phenotype were not dramatically changed during in vitro culture. LAG-3 knockout CAR-T cells displayed robust antigen-specific antitumor activity in cell culture and in murine xenograft model, which is comparable to standard CAR-T cells. Our study demonstrates an efficient approach to silence immune checkpoint in CAR-T cells via gene editing.
- 18 November 2015
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 61 (3) , 758-766
Decreased MIZ1 Expression in Severe Experimental Acute Pancreatitis: A Rat Study
We tested our hypothesis that Myc-interacting zinc finger protein 1 (MIZ1), a cell cycle regulator, suppressed inflammation, and therefore, represented a useful prognostic marker in patients with acute necrotizing pancreatitis (ANP) complicated by acute lung injury. Sprague–Dawley rats were randomly divided into control and ANP groups at different time points. The MIZ1 protein expression was measured by Western blot and ELISA, and confirmed using immunohistochemistry. The severity of pancreatic and lung injury was evaluated by the injury score and wet/dry weight ratio. The severity of disease was evaluated by serum C-reactive protein (CRP). The MPO activity of lung tissue amylase levels and the degree of inflammation were evaluated by serum tumor necrosis factor (TNF)-α and interleukin (IL)-6 expression. The risk due to multiple factors was investigated by relationship analysis. The serum levels of CRP, amylase, TNF-α, and IL-6 were gradually increased at 6, 24, and 48 h in ANP when compared with the control rats. The MIZ1 expressions were greatly decreased in ANP rats, especially at 24 h. Statistical analysis showed that there were time-dependent differences in ANP rats when compared with control rats (6 vs. 24 or 48 h, P < 0.01). MIZ1 showed close negative correlation with the degree of pancreatic and lung injury, serum amylase, CRP, TNF-α, and IL-6 (P < 0.01, respectively). The decreasing MIZ1 expression was closely correlated with inflammatory response, and development of ANP. Decreasing MIZ1 levels indicate a risk for ANP.
- 18 November 2015
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 61 (3) , 758-766
Decreased MIZ1 Expression in Severe Experimental Acute Pancreatitis: A Rat Study
We tested our hypothesis that Myc-interacting zinc finger protein 1 (MIZ1), a cell cycle regulator, suppressed inflammation, and therefore, represented a useful prognostic marker in patients with acute necrotizing pancreatitis (ANP) complicated by acute lung injury. Sprague–Dawley rats were randomly divided into control and ANP groups at different time points. The MIZ1 protein expression was measured by Western blot and ELISA, and confirmed using immunohistochemistry. The severity of pancreatic and lung injury was evaluated by the injury score and wet/dry weight ratio. The severity of disease was evaluated by serum C-reactive protein (CRP). The MPO activity of lung tissue amylase levels and the degree of inflammation were evaluated by serum tumor necrosis factor (TNF)-α and interleukin (IL)-6 expression. The risk due to multiple factors was investigated by relationship analysis. The serum levels of CRP, amylase, TNF-α, and IL-6 were gradually increased at 6, 24, and 48 h in ANP when compared with the control rats. The MIZ1 expressions were greatly decreased in ANP rats, especially at 24 h. Statistical analysis showed that there were time-dependent differences in ANP rats when compared with control rats (6 vs. 24 or 48 h, P < 0.01). MIZ1 showed close negative correlation with the degree of pancreatic and lung injury, serum amylase, CRP, TNF-α, and IL-6 (P < 0.01, respectively). The decreasing MIZ1 expression was closely correlated with inflammatory response, and development of ANP. Decreasing MIZ1 levels indicate a risk for ANP.